Chromone-lipoic acid conjugate: Neuroprotective agent having acceptable butyrylcholinesterase inhibition, antioxidant and copper-chelation activities

Daru. 2021 Jun;29(1):23-38. doi: 10.1007/s40199-020-00378-1. Epub 2021 Jan 9.

Abstract

Purpose: Alzheimer's disease (AD) is a multifaceted neurodegenerative disease. To target simultaneously multiple pathological processes involved in AD, natural-origin compounds with unique characteristics are promising scaffolds to develop novel multi-target compounds in the treatment of different neurodegenerative disease, especially AD. In this study, novel chromone-lipoic acid hybrids were prepared to find a new multifunctional lead structure for the treatment of AD.

Methods: Chromone-lipoic acid hybrids were prepared through click reaction and their neuroprotection and anticholinesterase activity were fully evaluated. The anti-amyloid aggregation, antioxidant and metal-chelation activities of the best compound were also investigated by standard methods to find a new multi-functional agent against AD.

Results: The primary biological screening demonstrated that all compounds had significant neuroprotection activity against H2O2-induced cell damage in PC12 cells. Compound 19 as the most potent butyrylcholinesterase (BuChE) inhibitor (IC50 = 7.55 μM) having significant neuroprotection activity as level as reference drug was selected for further biological evaluations. Docking and kinetic studies revealed non-competitive mixed-type inhibition of BuChE by compound 19. It could significantly reduce formation of the intracellular reactive oxygen species (ROS) and showed excellent reducing power (85.57 mM Fe+2), comparable with quercetin and lipoic acid. It could also moderately inhibit Aβ aggregation and selectively chelate with copper ions in 2:1 M ratio.

Conclusion: Compound 19 could be considered as a hopeful multifunctional agent for the further development gainst AD owing to the acceptable neuroprotective and anti-BuChE activity, moderate anti-Aβ aggregation activity, outstanding antioxidant activity as well as selective copper chelation ability. A new chromone-lipoic acid hybrid was synthesized as anti-Alzheimer agent with BuChE inhibitory activity, anti-Aβ aggregation, metal-chelation and antioxidant properties.

Keywords: Alzheimer’s disease; Antioxidant; Chromone; Lipoic acid; Multifunctional agent.

MeSH terms

  • Acetylcholinesterase / chemistry
  • Acetylcholinesterase / metabolism
  • Amyloid beta-Peptides / chemistry
  • Animals
  • Antioxidants / chemistry
  • Antioxidants / pharmacology*
  • Butyrylcholinesterase / chemistry
  • Butyrylcholinesterase / metabolism
  • Cell Survival / drug effects
  • Chelating Agents / chemistry
  • Chelating Agents / pharmacology*
  • Cholinesterase Inhibitors / chemistry
  • Cholinesterase Inhibitors / pharmacology*
  • Chromones / chemistry
  • Chromones / pharmacology*
  • Copper / chemistry
  • Neuroprotective Agents / chemistry
  • Neuroprotective Agents / pharmacology*
  • PC12 Cells
  • Peptide Fragments / chemistry
  • Rats
  • Reactive Oxygen Species / metabolism
  • Thioctic Acid / chemistry
  • Thioctic Acid / pharmacology*

Substances

  • Amyloid beta-Peptides
  • Antioxidants
  • Chelating Agents
  • Cholinesterase Inhibitors
  • Chromones
  • Neuroprotective Agents
  • Peptide Fragments
  • Reactive Oxygen Species
  • amyloid beta-protein (1-42)
  • Thioctic Acid
  • Copper
  • Acetylcholinesterase
  • Butyrylcholinesterase